LBPA, CNRS-ENS de Cachan, Cachan, France.
PLoS Comput Biol. 2011 Jun;7(6):e1002068. doi: 10.1371/journal.pcbi.1002068. Epub 2011 Jun 16.
The type III receptor tyrosine kinase (RTK) KIT plays a crucial role in the transmission of cellular signals through phosphorylation events that are associated with a switching of the protein conformation between inactive and active states. D816V KIT mutation is associated with various pathologies including mastocytosis and cancers. D816V-mutated KIT is constitutively active, and resistant to treatment with the anti-cancer drug Imatinib. To elucidate the activating molecular mechanism of this mutation, we applied a multi-approach procedure combining molecular dynamics (MD) simulations, normal modes analysis (NMA) and binding site prediction. Multiple 50-ns MD simulations of wild-type KIT and its mutant D816V were recorded using the inactive auto-inhibited structure of the protein, characteristic of type III RTKs. Computed free energy differences enabled us to quantify the impact of D816V on protein stability in the inactive state. We evidenced a local structural alteration of the activation loop (A-loop) upon mutation, and a long-range structural re-organization of the juxta-membrane region (JMR) followed by a weakening of the interaction network with the kinase domain. A thorough normal mode analysis of several MD conformations led to a plausible molecular rationale to propose that JMR is able to depart its auto-inhibitory position more easily in the mutant than in wild-type KIT and is thus able to promote kinase mutant dimerization without the need for extra-cellular ligand binding. Pocket detection at the surface of NMA-displaced conformations finally revealed that detachment of JMR from the kinase domain in the mutant was sufficient to open an access to the catalytic and substrate binding sites.
III 型受体酪氨酸激酶(RTK)KIT 在通过磷酸化事件传递细胞信号中起着至关重要的作用,这些磷酸化事件与蛋白构象在非活性和活性状态之间的转换有关。D816V KIT 突变与各种病理有关,包括肥大细胞增多症和癌症。D816V 突变的 KIT 是组成型激活的,并且对抗癌药物伊马替尼治疗有抗性。为了阐明这种突变的激活分子机制,我们应用了一种结合分子动力学(MD)模拟、正常模式分析(NMA)和结合位点预测的多方法程序。使用该蛋白的非活性自动抑制结构,对野生型 KIT 和其突变 D816V 进行了 50-ns 的 MD 模拟,该结构是 III 型 RTK 的特征。计算的自由能差异使我们能够量化 D816V 对无活性状态下蛋白稳定性的影响。我们证明了突变后激活环(A 环)的局部结构改变,以及近膜区(JMR)的长程结构重新组织,随后与激酶结构域的相互作用网络减弱。对几种 MD 构象的详细正常模式分析提供了一个合理的分子原理,即提议 JMR 在突变体中比在野生型 KIT 中更容易离开其自动抑制位置,因此能够促进激酶突变体二聚化,而无需额外的细胞外配体结合。在 NMA 位移构象表面的口袋检测最终表明,突变体中 JMR 与激酶结构域的分离足以打开通向催化和底物结合位点的通道。